Cracking the Code of Brain Infections with Advanced DNA Sequencing

BOSTON, MA – June 04, 2026 – For neurologists and infectious disease specialists, diagnosing infections of the central nervous system (CNS) represents one of modern medicine’s greatest challenges. The brain and spinal cord are shielded by the blood-brain barrier, making samples difficult to obtain, while the pathogens themselves can be rare, slow-growing, or masked by prior antibiotic treatments. Now, a pioneering technology is offering a powerful new lens to peer into this diagnostic black box, providing answers that have long eluded physicians.

Delve Bio, a spin-out from the University of California, San Francisco (UCSF), is making waves with its metagenomic next-generation sequencing (mNGS) platform, Delve Detect. The company is set to present compelling new data at the upcoming ASM Microbe 2026 conference, showcasing how its technology successfully identified the culprits behind several life-threatening CNS infections that stumped conventional methods. These cases highlight a significant shift in how complex infectious diseases may soon be managed.

The Limits of Conventional Diagnostics

Diagnosing infections like meningitis or encephalitis is a race against time, where every hour can impact long-term neurological outcomes. The traditional gold standard, microbial culture of cerebrospinal fluid (CSF), is fraught with limitations. Many pathogens are fastidious, meaning they refuse to grow in a lab dish. Furthermore, cultures can take days or weeks to yield a result, a dangerously long time for a patient with a rapidly progressing brain infection. Even more critically, if a patient has already received antibiotics, the chances of a successful culture plummet.

“The diagnostic yield from conventional CSF testing in complex cases is notoriously low, often under 30%,” explained a neurologist not affiliated with Delve Bio. “We are often left making educated guesses, treating empirically with broad-spectrum antibiotics that carry their own risks and may not even target the true pathogen.”

Targeted molecular tests like polymerase chain reaction (PCR) are faster but require the clinician to suspect a specific pathogen in advance. If the cause is an unexpected bacterium, virus, or fungus, the test will come back negative, sending doctors back to square one. This diagnostic gap leaves patients vulnerable to prolonged illness, invasive procedures, and irreversible neurological damage.

A New Era of Genomic Clarity

Metagenomic next-generation sequencing offers a fundamentally different approach. Instead of searching for a single, pre-determined suspect, mNGS sequences all the genetic material—both host and microbial—present in a single patient sample. By using powerful bioinformatics to filter out human DNA, it creates a comprehensive snapshot of every bacterium, virus, fungus, and parasite present. It is, in essence, a hypothesis-free investigation that can identify a culprit without any prior suspicion.

Delve Bio has refined this powerful technology into a clinical service designed for high-stakes scenarios. Its Delve Detect platform promises not only comprehensive pathogen detection but also speed, delivering results the day after a sample is received. This rapid turnaround is critical in CNS infections where treatment decisions are time-sensitive.

Further setting it apart is the inclusion of the Clinical Microbial Sequencing Board, an on-call team of infectious disease experts available to help treating physicians interpret the complex results. This addresses a major hurdle in mNGS adoption: the need for specialized expertise to distinguish a true pathogenic threat from a harmless commensal organism or a lab contaminant.

From Data to Diagnosis: Real-World Impact

The cases Delve Bio will present at ASM Microbe 2026 provide a stark illustration of the technology's impact. In one instance, a patient with a traumatic brain injury suffered a progressive respiratory decline, but all standard tests for an infectious cause came back negative. Delve Detect rapidly identified Pasteurella multocida, a bacterium often associated with animal bites, enabling physicians to initiate targeted antibiotic therapy and providing crucial diagnostic clarity.

Another case involved a pediatric patient with hydrocephalus and a ventriculoperitoneal shunt who developed a persistent fever and signs of meningitis. Due to prior antibiotic use, conventional tests were inconclusive, and clinicians were concerned about a shunt infection, a complication that often requires risky and costly neurosurgery to resolve. Delve Detect identified Mycobacterium abscessus, a notoriously difficult-to-treat pathogen, directly from the shunt fluid. This precise diagnosis allowed for the initiation of targeted anti-mycobacterial therapy and helped the patient avoid a shunt revision surgery.

In a third complex case, a patient recovering from influenza pneumonia experienced a severe downturn with headache, skull base bone infection, and stroke. Again, conventional diagnostics were unrevealing. Delve Detect identified Fusobacterium necrophorum, a fastidious anaerobic bacterium, despite the patient having already received antibiotics. This actionable result prompted physicians to expand antimicrobial coverage to include anaerobes and guided a successful, extended treatment course.

Navigating the Path to Widespread Adoption

Despite its clear potential, the road for mNGS from a niche research tool to a standard of care is challenging. Hurdles include the high cost of sequencing, the need for complex bioinformatics pipelines, and the ongoing battle for consistent reimbursement from insurance providers. “The technology is transformative, but its adoption hinges on demonstrating not just clinical utility but also cost-effectiveness,” noted a healthcare policy analyst.

This is where Delve Bio's strategic positioning becomes critical. The company was founded by a veritable who's who of genomics and infectious disease, including Drs. Charles Chiu, Joe DeRisi, and Pardis Sabeti, whose pioneering work laid the foundation for using mNGS in clinical settings. This scientific credibility, combined with backing from prominent venture capital firms like GV (formerly Google Ventures) and Section 32, provides the resources and strategic guidance needed to navigate the complex regulatory and commercial landscape.

By focusing on the most challenging diagnostic voids, such as CNS infections, Delve Bio is building a powerful case for the value of its technology. The ability to provide a definitive diagnosis can shorten hospital stays, prevent invasive surgeries, and enable the precise use of antibiotics—all factors that ultimately reduce overall healthcare costs and, most importantly, improve patient outcomes. As demonstrated by its latest clinical data, Delve Detect is not just identifying pathogens; it is providing the clarity needed to manage some of medicine's most confounding infections.